PMID- 37225483
OWN - NLM
STAT- MEDLINE
DCOM- 20240116
LR  - 20240215
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 63
IP  - 2
DP  - 2024 Jan 15
TI  - HLA-DRB1 Is Associated with Therapeutic Responsiveness in IgG4-related Disease.
PG  - 207-211
LID - 10.2169/internalmedicine.1847-23 [doi]
AB  - Objective Glucocorticoids are key drugs used in remission induction therapy for 
      IgG4-related disease (IgG4-RD). However, the therapeutic outcomes vary widely, 
      with some patients requiring long-term maintenance therapy and others relapsing 
      repeatedly, whereas still others can tolerate withdrawal. These variations 
      underscore the need for personalized treatment strategies for IgG4-RD. We 
      examined the relationship between human leukocyte antigen (HLA) genotypes and the 
      response to glucocorticoid treatment in patients with IgG4-RD. Methods Eighteen 
      IgG4-RD patients visiting our hospital were included in the study. Peripheral 
      blood samples were collected, HLA genotypes were determined, and the response to 
      glucocorticoid treatment (maintenance dose at the time of last observation, 
      glucocorticoid dose when the serum IgG4 level was the lowest after remission 
      induction therapy, and occurrence of relapse) was examined retrospectively. 
      Results The DQB1*12:01 genotypes were associated with a prednisolone maintenance 
      dose of <7 mg/day. A prednisolone dose >/=10 mg with a minimum serum IgG4 level was 
      significantly more common in B*40:01 and DRB1-GB-7-Val (DRB1*04:01, *04:03, 
      *04:05, *04:06, and *04:10) patients than other alleles. Relapse also tended to 
      be more common in DRB1-GB-7-Val carriers than other alleles. Conclusion These 
      data suggest that HLA-DRB1 is associated with glucocorticoid treatment 
      responsiveness and is important for follow-up monitoring of serum IgG4 levels 
      during glucocorticoid tapering. We believe that these data will contribute to the 
      future development of personalized medicine for IgG4-RD.
FAU - Yamamoto, Motohisa
AU  - Yamamoto M
AD  - Department of Rheumatology and Allergy, IMSUT Hospital, The Institute of Medical 
      Science, The University of Tokyo, Japan.
FAU - Tanaka, Tomonao
AU  - Tanaka T
AD  - Saitama Medical University, Japan.
FAU - Aochi, Satsuki
AU  - Aochi S
AD  - Department of Rheumatology and Allergy, IMSUT Hospital, The Institute of Medical 
      Science, The University of Tokyo, Japan.
FAU - Uehara, Masaaki
AU  - Uehara M
AD  - Department of Rheumatology and Allergy, IMSUT Hospital, The Institute of Medical 
      Science, The University of Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230524
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Glucocorticoids)
RN  - 0 (HLA-DRB1 Chains)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - 0 (Immunoglobulin G)
SB  - IM
MH  - Humans
MH  - *Glucocorticoids
MH  - *Immunoglobulin G4-Related Disease/drug therapy/genetics
MH  - HLA-DRB1 Chains/genetics/therapeutic use
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Remission Induction
MH  - Prednisolone
MH  - Immunoglobulin G
MH  - Recurrence
PMC - PMC10864075
OTO - NOTNLM
OT  - IgG4-related disease
OT  - glucocorticoid
OT  - human leucocyte antigen
OT  - relapse
OT  - valine
COIS- The authors state that they have no Conflict of Interest (COI).
EDAT- 2023/05/25 01:07
MHDA- 2024/01/16 06:42
PMCR- 2024/01/15
CRDT- 2023/05/24 21:53
PHST- 2024/01/16 06:42 [medline]
PHST- 2023/05/25 01:07 [pubmed]
PHST- 2023/05/24 21:53 [entrez]
PHST- 2024/01/15 00:00 [pmc-release]
AID - 10.2169/internalmedicine.1847-23 [doi]
PST - ppublish
SO  - Intern Med. 2024 Jan 15;63(2):207-211. doi: 10.2169/internalmedicine.1847-23. 
      Epub 2023 May 24.